Modulation of sphingosine-1-phosphate and apolipoprotein M levels in the plasma, liver and kidneys in streptozotocin-induced diabetic mice

Sphingosine‐1‐phosphate (S1P), a multifunctional bioactive lipid mediator, is involved in various diseases. Apolipoprotein M (ApoM) carries S1P on high‐density lipoprotein and modulates S1P metabolism to increase the total S1P mass in the body. Both S1P and ApoM are involved in diabetes.

[1]  M. Vadas,et al.  Loss of sphingosine kinase 1 predisposes to the onset of diabetes via promoting pancreatic β‐cell death in diet‐induced obese mice , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  M. Kurano,et al.  Liver involvement in sphingosine 1-phosphate dynamism revealed by adenoviral hepatic overexpression of apolipoprotein M. , 2013, Atherosclerosis.

[3]  J. Pfeilschifter,et al.  Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry Sphingosine 1-phosphate in Renal Diseases , 2022 .

[4]  A. Morris,et al.  Sphingosine 1-Phosphate (S1P) Regulates Glucose-stimulated Insulin Secretion in Pancreatic Beta Cells* , 2012, The Journal of Biological Chemistry.

[5]  Sarah Spiegel,et al.  Sphingosine-1-phosphate signaling and its role in disease. , 2012, Trends in cell biology.

[6]  U. Boggi,et al.  The pancreatic beta cells in human type 2 diabetes. , 2012, Advances in experimental medicine and biology.

[7]  S. Pitson,et al.  The sphingolipid rheostat: a potential target for improving pancreatic islet survival and function. , 2011, Endocrine, metabolic & immune disorders drug targets.

[8]  B. Dahlbäck,et al.  Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M , 2011, Proceedings of the National Academy of Sciences.

[9]  M. Bewley,et al.  Circulating sphingolipid biomarkers in models of type 1 diabetes , 2011, Journal of Lipid Research.

[10]  S. Tsui,et al.  Apolipoprotein M Gene (APOM) Polymorphism Modifies Metabolic and Disease Traits in Type 2 Diabetes , 2011, PloS one.

[11]  Suowen Xu,et al.  Determination of sphingosine kinase activity in biological samples by liquid chromatography-tandem mass spectrometry. , 2010, Biomedical chromatography : BMC.

[12]  James D. Johnson,et al.  Mechanisms of pancreatic beta-cell apoptosis in diabetes and its therapies. , 2010, Advances in experimental medicine and biology.

[13]  Y. Liu,et al.  Apolipoprotein M promoter polymorphisms alter promoter activity and confer the susceptibility to the development of type 1 diabetes. , 2009, Clinical biochemistry.

[14]  K. Feingold,et al.  Infection and inflammation decrease apolipoprotein M expression. , 2008, Atherosclerosis.

[15]  P. Nilsson-ehle,et al.  Liver X receptor agonist downregulates hepatic apoM expression in vivo and in vitro. , 2008, Biochemical and biophysical research communications.

[16]  Y. Yatomi.  Plasma sphingosine 1-phosphate metabolism and analysis. , 2008, Biochimica et biophysica acta.

[17]  P. Nilsson-ehle,et al.  Hyperglycemia down-regulates apolipoprotein M expression in vivo and in vitro. , 2007, Biochimica et biophysica acta.

[18]  Y. Liu,et al.  Single nucleotide polymorphisms in the proximal promoter region of apolipoprotein M gene (apoM) confer the susceptibility to development of type 2 diabetes in Han Chinese , 2007, Diabetes/metabolism research and reviews.

[19]  P. Nilsson-ehle,et al.  Suppression of apolipoprotein M expression and secretion in alloxan-diabetic mouse: Partial reversal by insulin. , 2006, Biochemical and biophysical research communications.

[20]  Y. Yatomi,et al.  Sphingosine 1-phosphate in vascular biology: possible therapeutic strategies to control vascular diseases. , 2006, Current pharmaceutical design.

[21]  S. Moestrup,et al.  Megalin is a receptor for apolipoprotein M, and kidney-specific megalin-deficiency confers urinary excretion of apolipoprotein M. , 2006, Molecular endocrinology.

[22]  Nils Welsh,et al.  Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. , 2005, Diabetes.

[23]  B. Dahlbäck,et al.  Characterization of apoM in normal and genetically modified mice Published, JLR Papers in Press, April 21, 2004. DOI 10.1194/jlr.M300451-JLR200 , 2004, Journal of Lipid Research.

[24]  N. Xu,et al.  Specific tissue expression and cellular localization of human apolipoprotein M as determined by in situ hybridization. , 2003, Acta histochemica.

[25]  B. Dahlbäck,et al.  A Novel Human Apolipoprotein (apoM)* , 1999, The Journal of Biological Chemistry.